Sagimet Biosciences (SGMT) Treasury Shares (2022 - 2026)
Sagimet Biosciences (SGMT) posted quarterly Treasury Shares of $1.1 million for Q1 2026, up 2.61% year-over-year from $1.1 million in Q1 2025, and up 35.78% quarter-over-quarter from $830077.0 in Q4 2025.
Sagimet Biosciences (SGMT) Treasury Shares (2022 - 2026) Analysis & Trends
Sagimet Biosciences' Treasury Shares history runs 5 years deep, the most recent figure standing at $1.1 million for Q1 2026.
- In Q1 2026, Treasury Shares rose 2.61% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $1.1 million (up 2.61% YoY), while the FY2025 annual figure was $830077.0, down 1.69% from the prior year.
- Treasury Shares for Q1 2026 stood at $1.1 million, up from $830077.0 in the prior quarter.
- The five-year high for Treasury Shares was $1.4 billion in Q2 2022, with the low at $816937.0 in Q3 2025.
- The 5-year median for Treasury Shares is $1.1 million (2024), against an average of $458.6 million.
- The sharpest annual moves came in 2024 and 2026: Treasury Shares tumbled 99.92% in 2024, then gained 2.61% in 2026.
- Sagimet Biosciences' Treasury Shares stood at $1.4 billion in 2022, then sank by 99.92% to $1.1 million in 2023, then decreased by 25.43% to $844382.0 in 2024, then dropped by 1.69% to $830077.0 in 2025, then surged by 35.78% to $1.1 million in 2026.
- Business Quant data shows SGMT's Treasury Shares at $1.1 million in Q1 2026, $830077.0 in Q4 2025, and $816937.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Sagimet Biosciences | 649.79 Mn | 649.79 Mn | - | 1.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.13 Mn |
| Jun 30, 2026 | 1.13 Mn |
| Mar 31, 2026 | 1.13 Mn |
| Mar 31, 2026 | 1.13 Mn |
| Dec 31, 2025 | 830,077.00 |
| Dec 31, 2025 | 830,077.00 |
| Sep 30, 2025 | 816,937.00 |
| Sep 30, 2025 | 816,937.00 |
| Jun 30, 2025 | 1.10 Mn |
| Jun 30, 2025 | 1.10 Mn |
| Mar 31, 2025 | 1.10 Mn |
| Mar 31, 2025 | 1.10 Mn |
| Dec 31, 2024 | 844,382.00 |
| Dec 31, 2024 | 844,382.00 |
| Sep 30, 2024 | 844,382.00 |
| Sep 30, 2024 | 844,382.00 |
| Jun 30, 2024 | 1.13 Mn |
| Jun 30, 2024 | 1.13 Mn |
| Mar 31, 2024 | 1.13 Mn |
| Mar 31, 2024 | 1.13 Mn |